# First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

Source: https://onco.cc/trials/nct05601726/  
OnCo record `nct05601726` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ABD-3001 in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Advanced BioDesign, now recruiting.

## Summary

First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients is a phase 1/2 interventional study registered as NCT05601726 by Advanced BioDesign, with 36 participants planned, started 2022-11-08 and due to reach its primary completion in 2026-06. Interventions recorded: ABD-3001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05601726
- Phase: 1/2
- Setting: First-In-Human, Open Label, Dose Escalation Study to Evaluate Safety, PK and PD of ABD-3001 As Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes Patients, Ineligible for Intensive or New Generation Targeted Therapy.
- Sponsor: Advanced BioDesign
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT05601726: https://clinicaltrials.gov/study/NCT05601726

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)

---
JSON: https://onco.cc/api/v1/entities/nct05601726.json